<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03462680</url>
  </required_header>
  <id_info>
    <org_study_id>N1613-I</org_study_id>
    <nct_id>NCT03462680</nct_id>
  </id_info>
  <brief_title>GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures</brief_title>
  <official_title>GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inflammation plays a central role in Parkinson's disease. The use of anti-inflammatory drugs&#xD;
      was found to reduce the risk of PD . Niacin may play an important role in reducing&#xD;
      inflammation in PD. The investigators also found that individuals with PD have a chronic&#xD;
      niacin deficiency .&#xD;
&#xD;
      The purposes of this study are to (1) examine the blood, urine and spinal fluid of persons&#xD;
      with Parkinson's to look for evidence of inflammation and; (2) whether 6 months of vitamin B3&#xD;
      supplements may reduce the inflammation and/or improve symptoms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inflammation plays a central role in Parkinson's disease (PD) pathology [1] as evidenced by&#xD;
      the presence of microglia in the substantia nigra in post-mortem samples [2] as well as&#xD;
      activated microglia and cytokines in clinical and animal studies [3]. The use of non-aspirin&#xD;
      non-steroidal anti-inflammatory drugs was found to reduce the risk of PD [4]. The&#xD;
      investigators recently identified an anti-inflammatory receptor GPR109A that is upregulated&#xD;
      in PD [5]. Niacin has a high affinity for this receptor, suggesting that it (niacin) may play&#xD;
      an important role in reducing inflammation in PD. The investigators also found that&#xD;
      individuals with PD have a chronic niacin deficiency [5]. Using seed funding from the local&#xD;
      PD chapter, the investigators obtained pilot data which suggested that restoring the&#xD;
      deficiency via over-the-counter (OTC) supplementation reduced inflammation and decreased the&#xD;
      severity of the disease symptoms [6]. In this VA-funded study, the investigators will&#xD;
      determine the effect of 6 months' OTC niacin supplementation on inflammation (as assessed in&#xD;
      the blood and spinal fluid) and severity of the PD symptoms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 28, 2016</start_date>
  <completion_date type="Actual">April 23, 2020</completion_date>
  <primary_completion_date type="Actual">April 23, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>There are two arms, niacin and placebo. They are double blind and randomized.</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Only Pharmacists keep the log of the drug dispensed. Everyone else is blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Unified Parkinson's Disease Rating Scale (UPDRS) Change</measure>
    <time_frame>at the recruitment and after 6 months</time_frame>
    <description>This is the Unified Parkinson's disease rating scale assessment. The investigators assess I, II, III and V components of the UPDRS. UPDRS 3 is motor skills. Higher scores mean worse outcome. A 0 is minimum and 120 is the maximum.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>REM Sleep Pattern</measure>
    <time_frame>baseline and after 6 months</time_frame>
    <description>This requires an instrument Zeo sleep monitor. Subjects are given instructions how to use it. Sleep sensor patches are supposed to be applied on forehead before going to sleep and the data of quality of sleep is captured overnight. The reported data captures the rapid eye movement (REM) sleep as a percentage.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Deep Sleep</measure>
    <time_frame>At baseline and after 6 months</time_frame>
    <description>This requires an instrument Zeo sleep monitor. Subjects are given instructions how to use it. Sleep sensor patches are supposed to be applied on forehead before going to sleep and the data of quality of sleep is captured overnight. The reported data captures the deep sleep percentage.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Light Sleep</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>This requires an instrument Zeo sleep monitor. Subjects are given instructions how to use it. Sleep sensor patches are supposed to be applied on forehead before going to sleep and the data of quality of sleep is captured overnight. The reported data captures the light sleep percentage.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sleep Time - Awake</measure>
    <time_frame>at baseline and 6 months</time_frame>
    <description>This requires an instrument Zeo sleep monitor. Subjects are given instructions how to use it. Sleep sensor patches are supposed to be applied on forehead before going to sleep and the data of quality of sleep is captured overnight. The reported data captures the awake time during night sleep percentage.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mini-Mental State Examination (MMSE) Change</measure>
    <time_frame>at baseline and after 6 months of treatment</time_frame>
    <description>It captures mental status and awareness of time, place and surrounding. A zero is minimum and 30 is maximum. Higher score indicates better cognition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stroop Test Change</measure>
    <time_frame>at the baseline and after 6 months of intervention</time_frame>
    <description>It captures understanding of color and its description within a certain time frame when letters and colors do not match. There are only two choices to pick from and the correct choices should be made to proceed to the next one. Correct choices are given one point and incorrect choices delete one point. Maximum number of correct choices per unit time are recorded. Three initial trials are given to understand the test. No minimum or maximum values. Higher numbers indicate better cognition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fatigue Severity Scale</measure>
    <time_frame>at baseline and after 6 months</time_frame>
    <description>Fatigue was rated from 0-7 in a fatigue questionnaire. A 0 being the least and 7 being the highest level of fatigue.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cerebrospinal Fluid Changes - Interleukin 6 (IL6)</measure>
    <time_frame>at baseline and after 6 months</time_frame>
    <description>IL-6 cytokine levels will be tested in cerebral spinal fluid (CSF) at baseline and 6 months after intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrospinal Fluid Changes - Interleukin 10 (IL-10)</measure>
    <time_frame>at baseline and after 6 months</time_frame>
    <description>IL-10 will be tested in cerebral spinal fluid (CSF) at baseline and 6 months after intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Niacin Metabolite in Urine - Niacin</measure>
    <time_frame>at baseline and after 6 months</time_frame>
    <description>Plasma and urine samples will be tested to report levels of niacin and its metabolites. Higher value indicates higher niacin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Niacin Metabolites in Urine - NAM Nicotinamide</measure>
    <time_frame>at baseline and 6 months</time_frame>
    <description>Plasma and urine samples will be tested to report levels of niacin and its metabolites. Higher value indicates higher niacin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Niacin Changes in Plasma - Niacin</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>Plasma and urine samples will be tested to report levels of niacin and its metabolites. Higher value indicates higher niacin levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Niacin Changes in Plasma - NUA Nicotinuric Acid</measure>
    <time_frame>at baseline and 6 months</time_frame>
    <description>Plasma and urine samples will be tested to report levels of niacin and its metabolites. Higher value indicates higher niacin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrospinal Fluid Changes - Interleukin 8 (IL8)</measure>
    <time_frame>at baseline and after 6 months</time_frame>
    <description>IL-8 cytokine levels will be tested in cerebral spinal fluid (CSF) at baseline and 6 months after intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Niacin Metabolite in Urine - Nicotinuric Acid NUA</measure>
    <time_frame>at baseline and after 6 months</time_frame>
    <description>Plasma and urine samples will be tested to report levels of niacin and its metabolites. Higher value indicates higher niacin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CSF Fluid Changes - Interleukin 1B (IL-1B)</measure>
    <time_frame>at baseline and 6 months</time_frame>
    <description>IL-1beta levels were tested in cerebral spinal fluid (CSF) at baseline and 6 months after intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrospinal Fluid (CSF) Changes - Macrophage Inflammatory Protein 1 Beta (MIP 1 Beta)</measure>
    <time_frame>at baseline and after 6 months</time_frame>
    <description>Inflammatory and non-inflammatory cytokines levels will be tested in cerebral spinal fluid (CSF) at baseline and 6 months after intervention. We are reporting levels of MIP-1 beta here.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Macrophage Changes</measure>
    <time_frame>at baseline and after 6 months</time_frame>
    <description>The blood is tested to report G-protein coupled receptor 109A (GPR109A) levels in macrophages in M1 and M2 populations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Niacin Metabolite Changes in Plasma - Nicotinamide (NAM)</measure>
    <time_frame>at baseline and after 6 months</time_frame>
    <description>Plasma and urine samples will be tested to report levels of niacin and its metabolites. Higher value indicates higher niacin levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CSF Changes in Interferon Gamma (IF-gamma)</measure>
    <time_frame>at baseline and after 6 months</time_frame>
    <description>Inflammatory and non-inflammatory cytokines levels will be tested in cerebral spinal fluid (CSF) at baseline and 6 months after intervention. We are reporting levels of IF-gamma beta here.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CSF Changes - Tumor Necrosis Factor - Alpha (TNF-alpha)</measure>
    <time_frame>at baseline and after 6 months</time_frame>
    <description>Inflammatory and non-inflammatory cytokines levels will be tested in cerebral spinal fluid (CSF) at baseline and 6 months after intervention. We are reporting levels of TNF-alpha here.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral Spinal Fluid Changes - Interferon Gamma Induced Protein -10 (IP-10)</measure>
    <time_frame>at baseline and after 6 months</time_frame>
    <description>Inflammatory and non-inflammatory cytokines levels will be tested in cerebral spinal fluid (CSF) at baseline and 6 months after intervention. We are reporting levels of IP-10 here.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral Spinal Fluid (CSF) Changes - Monocyte Chemoattractant Protein 4 (MCP4)</measure>
    <time_frame>at baseline and after 6 months</time_frame>
    <description>Inflammatory and non-inflammatory cytokines levels will be tested in cerebral spinal fluid (CSF) at baseline and 6 months after intervention. We are reporting levels of MCP4 here.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral Spinal Fluid (CSF) Changes - MIP1-alpha</measure>
    <time_frame>at baseline and after 6 months</time_frame>
    <description>Inflammatory and non-inflammatory cytokines levels will be tested in cerebral spinal fluid (CSF) at baseline and 6 months after intervention. We are reporting levels of MIP1-alpha here.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Cytokines - IF Gamma</measure>
    <time_frame>at baseline and after 6 months</time_frame>
    <description>Inflammatory and non-inflammatory cytokines levels will be tested in plasma at baseline and 6 months after intervention. We are reporting levels of IF-gamma here.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Cytokines - IL-10</measure>
    <time_frame>at baseline and after 6 months</time_frame>
    <description>Inflammatory and non-inflammatory cytokines levels will be tested in plasma at baseline and 6 months after intervention. We are reporting levels of IL-10 here.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Cytokines - IL1-B</measure>
    <time_frame>at baseline and after 6 months</time_frame>
    <description>Inflammatory and non-inflammatory cytokines levels will be tested in plasma at baseline and 6 months after intervention. We are reporting levels of IL-1B here.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Cytokines - IL-6</measure>
    <time_frame>at baseline and after 6 months</time_frame>
    <description>Inflammatory and non-inflammatory cytokines levels will be tested in plasma at baseline and 6 months after intervention. We are reporting levels of IL-6 here.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Cytokines - IL-8</measure>
    <time_frame>at baseline and after 6 Months</time_frame>
    <description>Inflammatory and non-inflammatory cytokines levels will be tested in plasma at baseline and 6 months after intervention. We are reporting levels of IL-8 here.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Cytokines - TNF-alpha</measure>
    <time_frame>at baseline and after 6 months</time_frame>
    <description>Inflammatory and non-inflammatory cytokines levels will be tested in plasma at baseline and 6 months after intervention. We are reporting levels of TNF-alpha here.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Cytokines - IP-10</measure>
    <time_frame>at baseline and after 6 months</time_frame>
    <description>Inflammatory and non-inflammatory cytokines levels will be tested in plasma at baseline and 6 months after intervention. We are reporting levels of IP-10 here.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Cytokines - MCP-4</measure>
    <time_frame>at baseline and after 6 months</time_frame>
    <description>Inflammatory and non-inflammatory cytokines levels will be tested in plasma at baseline and 6 months after intervention. We are reporting levels of MCP-4 here.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Cytokines - MIP1-alpha</measure>
    <time_frame>at baseline and after 6 months</time_frame>
    <description>Inflammatory and non-inflammatory cytokines levels will be tested in plasma at baseline and 6 months after intervention. We are reporting levels of MIP1-alpha here.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Cytokines - MIP1-beta</measure>
    <time_frame>at baseline and after 6 months</time_frame>
    <description>Inflammatory and non-inflammatory cytokines levels will be tested in plasma at baseline and 6 months after intervention. We are reporting levels of MIP1-beta here.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Levels - Serotonin</measure>
    <time_frame>at baseline and after 6 months</time_frame>
    <description>Plasma serotonin levels</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>niacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Niacin 250 mg is compared to placebo tablet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>niacin</intervention_name>
    <description>Niacin or nicotinic acid 250 mg tablets</description>
    <arm_group_label>niacin</arm_group_label>
    <other_name>vitamin B3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo tablet</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  PD subjects will be adult men and women diagnosed with idiopathic mild to moderately&#xD;
             severe PD defined as modified Hoehn &amp; Yahr Stages I-III (while &quot;On&quot;).&#xD;
&#xD;
               -  PD is defined according to the United Kingdom Brain Bank Criteria made at least&#xD;
                  six months prior to recruitment to the study.&#xD;
&#xD;
               -  PD features include the presence of at least two of the four cardinal clinical&#xD;
                  manifestations of the disease, which are tremor, rigidity, bradykinesia, and&#xD;
                  disturbances of posture or gait, without any other known or suspected cause of&#xD;
                  Parkinsonism.&#xD;
&#xD;
          -  Subjects should be stabilized on PD medication for at least 3 months before enrollment&#xD;
             into the study.&#xD;
&#xD;
          -  Subjects' PD drug prescriptions will not be altered nor withheld during the study,&#xD;
             i.e., they will be tested while &quot;On.&quot;&#xD;
&#xD;
          -  The patient will have signed informed consent.&#xD;
&#xD;
          -  Subjects who do not have PD (i.e., healthy or have other medical conditions such as&#xD;
             traumatic brain injury (TBI), stroke, or other syndromes in which inflammation plays a&#xD;
             role in the condition) will also be recruited as control subjects.&#xD;
&#xD;
          -  This will allow us to estimate whether these other conditions show similar or unique&#xD;
             inflammatory profile.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects will be excluded if they had previous brain surgery or other severe&#xD;
             neurological problems&#xD;
&#xD;
               -  intracerebral hemorrhage&#xD;
&#xD;
               -  traumatic brain injury&#xD;
&#xD;
               -  central nervous system malignancy&#xD;
&#xD;
               -  active central nervous system (CNS) infection&#xD;
&#xD;
               -  significant stroke&#xD;
&#xD;
               -  Alzheimer disease or any type of implanted stimulator including but not limited&#xD;
                  to Deep Brain Stimulator (DBS) or pacemaker&#xD;
&#xD;
          -  All subjects must be without evidence of dementia, defined as a score &gt; 24 the&#xD;
             Mini-Mental State Examination and able to understand test instructions&#xD;
&#xD;
          -  Subjects must not have functional blindness (inability to participate in gait and&#xD;
             visuomotor assessments) or lower limb amputation higher than the forefoot or any&#xD;
             orthopedic problem that precludes performance of physical tests&#xD;
&#xD;
          -  Allergic to niacin&#xD;
&#xD;
          -  Significant cardiac, pulmonary, hepatic, gastrointestinal, or renal disease&#xD;
&#xD;
               -  e.g., New York Heart Association Class III or IV congestive heart failure&#xD;
&#xD;
               -  endocarditis&#xD;
&#xD;
               -  pulmonary insufficiency symptomatic at rest or with mild physical exertion&#xD;
&#xD;
               -  acute or chronic hepatitis&#xD;
&#xD;
               -  renal failure requiring dialysis&#xD;
&#xD;
               -  second and third degree atrioventricular block or sick sinus syndrome), or&#xD;
                  diabetes are also exclusionary factors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chandramohan Wakade, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charlie Norwood VA Medical Center, Augusta, GA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charlie Norwood VA Medical Center, Augusta, GA</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 22, 2018</study_first_submitted>
  <study_first_submitted_qc>March 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2018</study_first_posted>
  <results_first_submitted>July 21, 2021</results_first_submitted>
  <results_first_submitted_qc>October 18, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 17, 2021</results_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>As the investigators request, we will share the data.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>One year after the study is closed.</ipd_time_frame>
    <ipd_access_criteria>When we are ready to publish, the data will be available.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 24, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/80/NCT03462680/Prot_SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 21, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/80/NCT03462680/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Niacin</title>
          <description>Niacin 250 mg is compared to placebo tablet.&#xD;
niacin: Niacin or nicotinic acid 250 mg tablets</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>placebo&#xD;
placebo: placebo tablet</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Niacin</title>
          <description>Niacin 250 mg is compared to placebo tablet.&#xD;
niacin: Niacin or nicotinic acid 250 mg tablets</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo&#xD;
placebo: placebo tablet</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="47"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.2" spread="6"/>
                    <measurement group_id="B2" value="68" spread="10.7"/>
                    <measurement group_id="B3" value="68.1" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>UPDRS III</title>
          <description>The minimum is 0 and the maximum is 120. Higher scores are worse outcomes.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.25" spread="15.8"/>
                    <measurement group_id="B2" value="22.4" spread="11.8"/>
                    <measurement group_id="B3" value="21.9" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Unified Parkinson's Disease Rating Scale (UPDRS) Change</title>
        <description>This is the Unified Parkinson's disease rating scale assessment. The investigators assess I, II, III and V components of the UPDRS. UPDRS 3 is motor skills. Higher scores mean worse outcome. A 0 is minimum and 120 is the maximum.</description>
        <time_frame>at the recruitment and after 6 months</time_frame>
        <population>Patients who completed 6 months were analyzed for this measure (39 subjects).</population>
        <group_list>
          <group group_id="O1">
            <title>Niacin</title>
            <description>Niacin 250 mg is compared to placebo tablet.&#xD;
niacin: Niacin or nicotinic acid 250 mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo&#xD;
placebo: placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Unified Parkinson's Disease Rating Scale (UPDRS) Change</title>
          <description>This is the Unified Parkinson's disease rating scale assessment. The investigators assess I, II, III and V components of the UPDRS. UPDRS 3 is motor skills. Higher scores mean worse outcome. A 0 is minimum and 120 is the maximum.</description>
          <population>Patients who completed 6 months were analyzed for this measure (39 subjects).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.25" spread="15.8"/>
                    <measurement group_id="O2" value="22.4" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8" spread="12.4"/>
                    <measurement group_id="O2" value="22.31" spread="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>REM Sleep Pattern</title>
        <description>This requires an instrument Zeo sleep monitor. Subjects are given instructions how to use it. Sleep sensor patches are supposed to be applied on forehead before going to sleep and the data of quality of sleep is captured overnight. The reported data captures the rapid eye movement (REM) sleep as a percentage.</description>
        <time_frame>baseline and after 6 months</time_frame>
        <population>Patients who completed 6 months were analyzed for this measure (39 subjects).</population>
        <group_list>
          <group group_id="O1">
            <title>Niacin</title>
            <description>Niacin 250 mg is compared to placebo tablet.&#xD;
niacin: Niacin or nicotinic acid 250 mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo&#xD;
placebo: placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>REM Sleep Pattern</title>
          <description>This requires an instrument Zeo sleep monitor. Subjects are given instructions how to use it. Sleep sensor patches are supposed to be applied on forehead before going to sleep and the data of quality of sleep is captured overnight. The reported data captures the rapid eye movement (REM) sleep as a percentage.</description>
          <population>Patients who completed 6 months were analyzed for this measure (39 subjects).</population>
          <units>percentage of sleep time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.09" spread="13.36"/>
                    <measurement group_id="O2" value="15.83" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.1" spread="11.6"/>
                    <measurement group_id="O2" value="21.45" spread="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Deep Sleep</title>
        <description>This requires an instrument Zeo sleep monitor. Subjects are given instructions how to use it. Sleep sensor patches are supposed to be applied on forehead before going to sleep and the data of quality of sleep is captured overnight. The reported data captures the deep sleep percentage.</description>
        <time_frame>At baseline and after 6 months</time_frame>
        <population>Patients who completed 6 months were analyzed for this measure (39 subjects).</population>
        <group_list>
          <group group_id="O1">
            <title>Niacin</title>
            <description>Niacin 250 mg is compared to placebo tablet.&#xD;
niacin: Niacin or nicotinic acid 250 mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo&#xD;
placebo: placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Deep Sleep</title>
          <description>This requires an instrument Zeo sleep monitor. Subjects are given instructions how to use it. Sleep sensor patches are supposed to be applied on forehead before going to sleep and the data of quality of sleep is captured overnight. The reported data captures the deep sleep percentage.</description>
          <population>Patients who completed 6 months were analyzed for this measure (39 subjects).</population>
          <units>percentage of deep sleep time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.17" spread="5.11"/>
                    <measurement group_id="O2" value="8.48" spread="6.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.28" spread="16.27"/>
                    <measurement group_id="O2" value="8.32" spread="6.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Light Sleep</title>
        <description>This requires an instrument Zeo sleep monitor. Subjects are given instructions how to use it. Sleep sensor patches are supposed to be applied on forehead before going to sleep and the data of quality of sleep is captured overnight. The reported data captures the light sleep percentage.</description>
        <time_frame>baseline and 6 months</time_frame>
        <population>Patients who completed 6 months were analyzed for this measure (39 subjects).</population>
        <group_list>
          <group group_id="O1">
            <title>Niacin</title>
            <description>Niacin 250 mg is compared to placebo tablet.&#xD;
niacin: Niacin or nicotinic acid 250 mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo&#xD;
placebo: placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Light Sleep</title>
          <description>This requires an instrument Zeo sleep monitor. Subjects are given instructions how to use it. Sleep sensor patches are supposed to be applied on forehead before going to sleep and the data of quality of sleep is captured overnight. The reported data captures the light sleep percentage.</description>
          <population>Patients who completed 6 months were analyzed for this measure (39 subjects).</population>
          <units>percentage of light sleep time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.2" spread="17.9"/>
                    <measurement group_id="O2" value="53.5" spread="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.9" spread="15.6"/>
                    <measurement group_id="O2" value="47.5" spread="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sleep Time - Awake</title>
        <description>This requires an instrument Zeo sleep monitor. Subjects are given instructions how to use it. Sleep sensor patches are supposed to be applied on forehead before going to sleep and the data of quality of sleep is captured overnight. The reported data captures the awake time during night sleep percentage.</description>
        <time_frame>at baseline and 6 months</time_frame>
        <population>Patients who completed 6 months were analyzed for this measure (39 subjects).</population>
        <group_list>
          <group group_id="O1">
            <title>Niacin</title>
            <description>Niacin 250 mg is compared to placebo tablet.&#xD;
niacin: Niacin or nicotinic acid 250 mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo&#xD;
placebo: placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Time - Awake</title>
          <description>This requires an instrument Zeo sleep monitor. Subjects are given instructions how to use it. Sleep sensor patches are supposed to be applied on forehead before going to sleep and the data of quality of sleep is captured overnight. The reported data captures the awake time during night sleep percentage.</description>
          <population>Patients who completed 6 months were analyzed for this measure (39 subjects).</population>
          <units>percentage of awake-sleep time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2" spread="23.23"/>
                    <measurement group_id="O2" value="21.95" spread="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" spread="10.3"/>
                    <measurement group_id="O2" value="23" spread="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mini-Mental State Examination (MMSE) Change</title>
        <description>It captures mental status and awareness of time, place and surrounding. A zero is minimum and 30 is maximum. Higher score indicates better cognition.</description>
        <time_frame>at baseline and after 6 months of treatment</time_frame>
        <population>Patients who completed 6 months were analyzed for this measure (39 subjects).</population>
        <group_list>
          <group group_id="O1">
            <title>Niacin</title>
            <description>Niacin 250 mg is compared to placebo tablet.&#xD;
niacin: Niacin or nicotinic acid 250 mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo&#xD;
placebo: placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Mini-Mental State Examination (MMSE) Change</title>
          <description>It captures mental status and awareness of time, place and surrounding. A zero is minimum and 30 is maximum. Higher score indicates better cognition.</description>
          <population>Patients who completed 6 months were analyzed for this measure (39 subjects).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.94" spread="0.24"/>
                    <measurement group_id="O2" value="29.81" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.94" spread="0.24"/>
                    <measurement group_id="O2" value="29.71" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Stroop Test Change</title>
        <description>It captures understanding of color and its description within a certain time frame when letters and colors do not match. There are only two choices to pick from and the correct choices should be made to proceed to the next one. Correct choices are given one point and incorrect choices delete one point. Maximum number of correct choices per unit time are recorded. Three initial trials are given to understand the test. No minimum or maximum values. Higher numbers indicate better cognition.</description>
        <time_frame>at the baseline and after 6 months of intervention</time_frame>
        <population>Stroop test was added after recruitment of few subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Niacin</title>
            <description>Niacin 250 mg is compared to placebo tablet.&#xD;
niacin: Niacin or nicotinic acid 250 mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo&#xD;
placebo: placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Stroop Test Change</title>
          <description>It captures understanding of color and its description within a certain time frame when letters and colors do not match. There are only two choices to pick from and the correct choices should be made to proceed to the next one. Correct choices are given one point and incorrect choices delete one point. Maximum number of correct choices per unit time are recorded. Three initial trials are given to understand the test. No minimum or maximum values. Higher numbers indicate better cognition.</description>
          <population>Stroop test was added after recruitment of few subjects.</population>
          <units>number of correct responses/unit time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.18" spread="7.92"/>
                    <measurement group_id="O2" value="8.13" spread="6.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.37" spread="5.6"/>
                    <measurement group_id="O2" value="8.72" spread="6.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Fatigue Severity Scale</title>
        <description>Fatigue was rated from 0-7 in a fatigue questionnaire. A 0 being the least and 7 being the highest level of fatigue.</description>
        <time_frame>at baseline and after 6 months</time_frame>
        <population>Patients who completed 6 months were analyzed for this measure (39 subjects).</population>
        <group_list>
          <group group_id="O1">
            <title>Niacin</title>
            <description>Niacin 250 mg is compared to placebo tablet.&#xD;
niacin: Niacin or nicotinic acid 250 mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo&#xD;
placebo: placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Fatigue Severity Scale</title>
          <description>Fatigue was rated from 0-7 in a fatigue questionnaire. A 0 being the least and 7 being the highest level of fatigue.</description>
          <population>Patients who completed 6 months were analyzed for this measure (39 subjects).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.3" spread="11.99"/>
                    <measurement group_id="O2" value="36.7" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.5" spread="10.99"/>
                    <measurement group_id="O2" value="36.7" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cerebrospinal Fluid Changes - Interleukin 6 (IL6)</title>
        <description>IL-6 cytokine levels will be tested in cerebral spinal fluid (CSF) at baseline and 6 months after intervention.</description>
        <time_frame>at baseline and after 6 months</time_frame>
        <population>Not all subjects donated CSF. All CSF samples are recorded here.</population>
        <group_list>
          <group group_id="O1">
            <title>Niacin</title>
            <description>Niacin 250 mg is compared to placebo tablet.&#xD;
niacin: Niacin or nicotinic acid 250 mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo&#xD;
placebo: placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Cerebrospinal Fluid Changes - Interleukin 6 (IL6)</title>
          <description>IL-6 cytokine levels will be tested in cerebral spinal fluid (CSF) at baseline and 6 months after intervention.</description>
          <population>Not all subjects donated CSF. All CSF samples are recorded here.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.5"/>
                    <measurement group_id="O2" value="1.9" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.37"/>
                    <measurement group_id="O2" value="1.2" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cerebrospinal Fluid Changes - Interleukin 10 (IL-10)</title>
        <description>IL-10 will be tested in cerebral spinal fluid (CSF) at baseline and 6 months after intervention.</description>
        <time_frame>at baseline and after 6 months</time_frame>
        <population>Not all subjects donated CSF. All CSF samples are recorded here.</population>
        <group_list>
          <group group_id="O1">
            <title>Niacin</title>
            <description>Niacin 250 mg is compared to placebo tablet.&#xD;
niacin: Niacin or nicotinic acid 250 mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo&#xD;
placebo: placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Cerebrospinal Fluid Changes - Interleukin 10 (IL-10)</title>
          <description>IL-10 will be tested in cerebral spinal fluid (CSF) at baseline and 6 months after intervention.</description>
          <population>Not all subjects donated CSF. All CSF samples are recorded here.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" spread="0.64"/>
                    <measurement group_id="O2" value="0.13" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.01"/>
                    <measurement group_id="O2" value="0.08" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Niacin Metabolite in Urine - Niacin</title>
        <description>Plasma and urine samples will be tested to report levels of niacin and its metabolites. Higher value indicates higher niacin levels</description>
        <time_frame>at baseline and after 6 months</time_frame>
        <population>A subset of groups were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Niacin</title>
            <description>Niacin 250 mg is compared to placebo tablet.&#xD;
niacin: Niacin or nicotinic acid 250 mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo&#xD;
placebo: placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Niacin Metabolite in Urine - Niacin</title>
          <description>Plasma and urine samples will be tested to report levels of niacin and its metabolites. Higher value indicates higher niacin levels</description>
          <population>A subset of groups were analyzed.</population>
          <units>ng/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1826.8" spread="663.2"/>
                    <measurement group_id="O2" value="1533" spread="895.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1913.8" spread="481"/>
                    <measurement group_id="O2" value="1660.6" spread="431.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Niacin Metabolites in Urine - NAM Nicotinamide</title>
        <description>Plasma and urine samples will be tested to report levels of niacin and its metabolites. Higher value indicates higher niacin levels</description>
        <time_frame>at baseline and 6 months</time_frame>
        <population>A subset of subjects were randomly selected for this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Niacin</title>
            <description>Niacin 250 mg is compared to placebo tablet.&#xD;
niacin: Niacin or nicotinic acid 250 mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo&#xD;
placebo: placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Niacin Metabolites in Urine - NAM Nicotinamide</title>
          <description>Plasma and urine samples will be tested to report levels of niacin and its metabolites. Higher value indicates higher niacin levels</description>
          <population>A subset of subjects were randomly selected for this analysis.</population>
          <units>ng/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="815.5" spread="1155"/>
                    <measurement group_id="O2" value="205.8" spread="312.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1140.3" spread="1058.4"/>
                    <measurement group_id="O2" value="685.4" spread="709.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Niacin Changes in Plasma - Niacin</title>
        <description>Plasma and urine samples will be tested to report levels of niacin and its metabolites. Higher value indicates higher niacin levels.</description>
        <time_frame>baseline and 6 months</time_frame>
        <population>A subset of subjects were randomly selected for this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Niacin</title>
            <description>Niacin 250 mg is compared to placebo tablet.&#xD;
niacin: Niacin or nicotinic acid 250 mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo&#xD;
placebo: placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Niacin Changes in Plasma - Niacin</title>
          <description>Plasma and urine samples will be tested to report levels of niacin and its metabolites. Higher value indicates higher niacin levels.</description>
          <population>A subset of subjects were randomly selected for this analysis.</population>
          <units>nM/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.5" spread="95.96"/>
                    <measurement group_id="O2" value="55.8" spread="88.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.83" spread="92.4"/>
                    <measurement group_id="O2" value="92.2" spread="59.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Niacin Changes in Plasma - NUA Nicotinuric Acid</title>
        <description>Plasma and urine samples will be tested to report levels of niacin and its metabolites. Higher value indicates higher niacin levels</description>
        <time_frame>at baseline and 6 months</time_frame>
        <population>Plasma and urine samples will be tested to report levels of niacin and its metabolites. Higher value indicates higher niacin levels. Undetectable values are reported as zero. A subset of the groups were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Niacin</title>
            <description>Niacin 250 mg is compared to placebo tablet.&#xD;
niacin: Niacin or nicotinic acid 250 mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo&#xD;
placebo: placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Niacin Changes in Plasma - NUA Nicotinuric Acid</title>
          <description>Plasma and urine samples will be tested to report levels of niacin and its metabolites. Higher value indicates higher niacin levels</description>
          <population>Plasma and urine samples will be tested to report levels of niacin and its metabolites. Higher value indicates higher niacin levels. Undetectable values are reported as zero. A subset of the groups were analyzed.</population>
          <units>nM/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="4.99" spread="17.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="313.9" spread="442.7"/>
                    <measurement group_id="O2" value="0.38" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cerebrospinal Fluid Changes - Interleukin 8 (IL8)</title>
        <description>IL-8 cytokine levels will be tested in cerebral spinal fluid (CSF) at baseline and 6 months after intervention.</description>
        <time_frame>at baseline and after 6 months</time_frame>
        <population>Not all subjects donated CSF. All CSF samples are recorded here.</population>
        <group_list>
          <group group_id="O1">
            <title>Niacin</title>
            <description>Niacin 250 mg is compared to placebo tablet.&#xD;
niacin: Niacin or nicotinic acid 250 mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo&#xD;
placebo: placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Cerebrospinal Fluid Changes - Interleukin 8 (IL8)</title>
          <description>IL-8 cytokine levels will be tested in cerebral spinal fluid (CSF) at baseline and 6 months after intervention.</description>
          <population>Not all subjects donated CSF. All CSF samples are recorded here.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.9" spread="5.27"/>
                    <measurement group_id="O2" value="102.5" spread="74.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.6" spread="51.2"/>
                    <measurement group_id="O2" value="77.9" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Niacin Metabolite in Urine - Nicotinuric Acid NUA</title>
        <description>Plasma and urine samples will be tested to report levels of niacin and its metabolites. Higher value indicates higher niacin levels</description>
        <time_frame>at baseline and after 6 months</time_frame>
        <population>Plasma and urine samples will be tested to report levels of niacin and its metabolites. Higher value indicates higher niacin levels. A subset of the groups were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Niacin</title>
            <description>Niacin 250 mg is compared to placebo tablet.&#xD;
niacin: Niacin or nicotinic acid 250 mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo&#xD;
placebo: placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Niacin Metabolite in Urine - Nicotinuric Acid NUA</title>
          <description>Plasma and urine samples will be tested to report levels of niacin and its metabolites. Higher value indicates higher niacin levels</description>
          <population>Plasma and urine samples will be tested to report levels of niacin and its metabolites. Higher value indicates higher niacin levels. A subset of the groups were analyzed.</population>
          <units>ng/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3565.3" spread="7364.8"/>
                    <measurement group_id="O2" value="1021.8" spread="4538.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20132.9" spread="26789.4"/>
                    <measurement group_id="O2" value="2803.7" spread="8459.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CSF Fluid Changes - Interleukin 1B (IL-1B)</title>
        <description>IL-1beta levels were tested in cerebral spinal fluid (CSF) at baseline and 6 months after intervention.</description>
        <time_frame>at baseline and 6 months</time_frame>
        <population>Not all subjects donated CSF. All CSF samples are recorded here.</population>
        <group_list>
          <group group_id="O1">
            <title>Niacin</title>
            <description>Niacin 250 mg is compared to placebo tablet.&#xD;
niacin: Niacin or nicotinic acid 250 mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo&#xD;
placebo: placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>CSF Fluid Changes - Interleukin 1B (IL-1B)</title>
          <description>IL-1beta levels were tested in cerebral spinal fluid (CSF) at baseline and 6 months after intervention.</description>
          <population>Not all subjects donated CSF. All CSF samples are recorded here.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" spread="0.8"/>
                    <measurement group_id="O2" value="0.28" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.06"/>
                    <measurement group_id="O2" value="0.22" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cerebrospinal Fluid (CSF) Changes - Macrophage Inflammatory Protein 1 Beta (MIP 1 Beta)</title>
        <description>Inflammatory and non-inflammatory cytokines levels will be tested in cerebral spinal fluid (CSF) at baseline and 6 months after intervention. We are reporting levels of MIP-1 beta here.</description>
        <time_frame>at baseline and after 6 months</time_frame>
        <population>Not all subjects donated CSF. All CSF samples are recorded here.</population>
        <group_list>
          <group group_id="O1">
            <title>Niacin</title>
            <description>Niacin 250 mg is compared to placebo tablet.&#xD;
niacin: Niacin or nicotinic acid 250 mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo&#xD;
placebo: placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Cerebrospinal Fluid (CSF) Changes - Macrophage Inflammatory Protein 1 Beta (MIP 1 Beta)</title>
          <description>Inflammatory and non-inflammatory cytokines levels will be tested in cerebral spinal fluid (CSF) at baseline and 6 months after intervention. We are reporting levels of MIP-1 beta here.</description>
          <population>Not all subjects donated CSF. All CSF samples are recorded here.</population>
          <units>pico grams per ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7" spread="5.02"/>
                    <measurement group_id="O2" value="9.3" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9" spread="1.3"/>
                    <measurement group_id="O2" value="7.7" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Macrophage Changes</title>
        <description>The blood is tested to report G-protein coupled receptor 109A (GPR109A) levels in macrophages in M1 and M2 populations.</description>
        <time_frame>at baseline and after 6 months</time_frame>
        <population>A subset of subjects were randomly selected for this measure and all the data is recorded here that was captured.</population>
        <group_list>
          <group group_id="O1">
            <title>Niacin</title>
            <description>Niacin 250 mg is compared to placebo tablet.&#xD;
niacin: Niacin or nicotinic acid 250 mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo&#xD;
placebo: placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Macrophage Changes</title>
          <description>The blood is tested to report G-protein coupled receptor 109A (GPR109A) levels in macrophages in M1 and M2 populations.</description>
          <population>A subset of subjects were randomly selected for this measure and all the data is recorded here that was captured.</population>
          <units>percentage of macrophages</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.08" spread="4.08"/>
                    <measurement group_id="O2" value="56" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.92" spread="3.9"/>
                    <measurement group_id="O2" value="54.5" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Niacin Metabolite Changes in Plasma - Nicotinamide (NAM)</title>
        <description>Plasma and urine samples will be tested to report levels of niacin and its metabolites. Higher value indicates higher niacin levels.</description>
        <time_frame>at baseline and after 6 months</time_frame>
        <population>A subset of subjects were randomly selected for this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Niacin</title>
            <description>Niacin 250 mg is compared to placebo tablet.&#xD;
niacin: Niacin or nicotinic acid 250 mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo&#xD;
placebo: placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Niacin Metabolite Changes in Plasma - Nicotinamide (NAM)</title>
          <description>Plasma and urine samples will be tested to report levels of niacin and its metabolites. Higher value indicates higher niacin levels.</description>
          <population>A subset of subjects were randomly selected for this analysis.</population>
          <units>uM/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="0.30"/>
                    <measurement group_id="O2" value="0.34" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" spread="0.46"/>
                    <measurement group_id="O2" value="0.38" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CSF Changes in Interferon Gamma (IF-gamma)</title>
        <description>Inflammatory and non-inflammatory cytokines levels will be tested in cerebral spinal fluid (CSF) at baseline and 6 months after intervention. We are reporting levels of IF-gamma beta here.</description>
        <time_frame>at baseline and after 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Niacin</title>
            <description>Niacin 250 mg is compared to placebo tablet.&#xD;
niacin: Niacin or nicotinic acid 250 mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo&#xD;
placebo: placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>CSF Changes in Interferon Gamma (IF-gamma)</title>
          <description>Inflammatory and non-inflammatory cytokines levels will be tested in cerebral spinal fluid (CSF) at baseline and 6 months after intervention. We are reporting levels of IF-gamma beta here.</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.3"/>
                    <measurement group_id="O2" value="0.39" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="2.3"/>
                    <measurement group_id="O2" value="0.89" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CSF Changes - Tumor Necrosis Factor - Alpha (TNF-alpha)</title>
        <description>Inflammatory and non-inflammatory cytokines levels will be tested in cerebral spinal fluid (CSF) at baseline and 6 months after intervention. We are reporting levels of TNF-alpha here.</description>
        <time_frame>at baseline and after 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Niacin</title>
            <description>Niacin 250 mg is compared to placebo tablet.&#xD;
niacin: Niacin or nicotinic acid 250 mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo&#xD;
placebo: placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>CSF Changes - Tumor Necrosis Factor - Alpha (TNF-alpha)</title>
          <description>Inflammatory and non-inflammatory cytokines levels will be tested in cerebral spinal fluid (CSF) at baseline and 6 months after intervention. We are reporting levels of TNF-alpha here.</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" spread="0.87"/>
                    <measurement group_id="O2" value="0.18" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.05"/>
                    <measurement group_id="O2" value="0.2" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cerebral Spinal Fluid Changes - Interferon Gamma Induced Protein -10 (IP-10)</title>
        <description>Inflammatory and non-inflammatory cytokines levels will be tested in cerebral spinal fluid (CSF) at baseline and 6 months after intervention. We are reporting levels of IP-10 here.</description>
        <time_frame>at baseline and after 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Niacin</title>
            <description>Niacin 250 mg is compared to placebo tablet.&#xD;
niacin: Niacin or nicotinic acid 250 mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo&#xD;
placebo: placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Cerebral Spinal Fluid Changes - Interferon Gamma Induced Protein -10 (IP-10)</title>
          <description>Inflammatory and non-inflammatory cytokines levels will be tested in cerebral spinal fluid (CSF) at baseline and 6 months after intervention. We are reporting levels of IP-10 here.</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="359.8" spread="193.5"/>
                    <measurement group_id="O2" value="512" spread="304.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="936.2" spread="1018"/>
                    <measurement group_id="O2" value="514.5" spread="351.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cerebral Spinal Fluid (CSF) Changes - Monocyte Chemoattractant Protein 4 (MCP4)</title>
        <description>Inflammatory and non-inflammatory cytokines levels will be tested in cerebral spinal fluid (CSF) at baseline and 6 months after intervention. We are reporting levels of MCP4 here.</description>
        <time_frame>at baseline and after 6 months</time_frame>
        <population>Not all subjects donated CSF. All CSF samples are recorded here.</population>
        <group_list>
          <group group_id="O1">
            <title>Niacin</title>
            <description>Niacin 250 mg is compared to placebo tablet.&#xD;
niacin: Niacin or nicotinic acid 250 mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo&#xD;
placebo: placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Cerebral Spinal Fluid (CSF) Changes - Monocyte Chemoattractant Protein 4 (MCP4)</title>
          <description>Inflammatory and non-inflammatory cytokines levels will be tested in cerebral spinal fluid (CSF) at baseline and 6 months after intervention. We are reporting levels of MCP4 here.</description>
          <population>Not all subjects donated CSF. All CSF samples are recorded here.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6" spread="2.03"/>
                    <measurement group_id="O2" value="7.3" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="5.6"/>
                    <measurement group_id="O2" value="6.7" spread="5.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cerebral Spinal Fluid (CSF) Changes - MIP1-alpha</title>
        <description>Inflammatory and non-inflammatory cytokines levels will be tested in cerebral spinal fluid (CSF) at baseline and 6 months after intervention. We are reporting levels of MIP1-alpha here.</description>
        <time_frame>at baseline and after 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Niacin</title>
            <description>Niacin 250 mg is compared to placebo tablet.&#xD;
niacin: Niacin or nicotinic acid 250 mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo&#xD;
placebo: placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Cerebral Spinal Fluid (CSF) Changes - MIP1-alpha</title>
          <description>Inflammatory and non-inflammatory cytokines levels will be tested in cerebral spinal fluid (CSF) at baseline and 6 months after intervention. We are reporting levels of MIP1-alpha here.</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8" spread="6"/>
                    <measurement group_id="O2" value="18.7" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5" spread="18.2"/>
                    <measurement group_id="O2" value="17.3" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Cytokines - IF Gamma</title>
        <description>Inflammatory and non-inflammatory cytokines levels will be tested in plasma at baseline and 6 months after intervention. We are reporting levels of IF-gamma here.</description>
        <time_frame>at baseline and after 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Niacin</title>
            <description>Niacin 250 mg is compared to placebo tablet.&#xD;
niacin: Niacin or nicotinic acid 250 mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo&#xD;
placebo: placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Cytokines - IF Gamma</title>
          <description>Inflammatory and non-inflammatory cytokines levels will be tested in plasma at baseline and 6 months after intervention. We are reporting levels of IF-gamma here.</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2" spread="15.6"/>
                    <measurement group_id="O2" value="21" spread="33.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.8" spread="287.7"/>
                    <measurement group_id="O2" value="15.95" spread="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Cytokines - IL-10</title>
        <description>Inflammatory and non-inflammatory cytokines levels will be tested in plasma at baseline and 6 months after intervention. We are reporting levels of IL-10 here.</description>
        <time_frame>at baseline and after 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Niacin</title>
            <description>Niacin 250 mg is compared to placebo tablet.&#xD;
niacin: Niacin or nicotinic acid 250 mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo&#xD;
placebo: placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Cytokines - IL-10</title>
          <description>Inflammatory and non-inflammatory cytokines levels will be tested in plasma at baseline and 6 months after intervention. We are reporting levels of IL-10 here.</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread="0.28"/>
                    <measurement group_id="O2" value="0.41" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.64"/>
                    <measurement group_id="O2" value="0.41" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Cytokines - IL1-B</title>
        <description>Inflammatory and non-inflammatory cytokines levels will be tested in plasma at baseline and 6 months after intervention. We are reporting levels of IL-1B here.</description>
        <time_frame>at baseline and after 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Niacin</title>
            <description>Niacin 250 mg is compared to placebo tablet.&#xD;
niacin: Niacin or nicotinic acid 250 mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo&#xD;
placebo: placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Cytokines - IL1-B</title>
          <description>Inflammatory and non-inflammatory cytokines levels will be tested in plasma at baseline and 6 months after intervention. We are reporting levels of IL-1B here.</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" spread="0.34"/>
                    <measurement group_id="O2" value="0.37" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.17"/>
                    <measurement group_id="O2" value="0.29" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Cytokines - IL-6</title>
        <description>Inflammatory and non-inflammatory cytokines levels will be tested in plasma at baseline and 6 months after intervention. We are reporting levels of IL-6 here.</description>
        <time_frame>at baseline and after 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Niacin</title>
            <description>Niacin 250 mg is compared to placebo tablet.&#xD;
niacin: Niacin or nicotinic acid 250 mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo&#xD;
placebo: placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Cytokines - IL-6</title>
          <description>Inflammatory and non-inflammatory cytokines levels will be tested in plasma at baseline and 6 months after intervention. We are reporting levels of IL-6 here.</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="17.8"/>
                    <measurement group_id="O2" value="8.7" spread="34.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.97" spread="4.25"/>
                    <measurement group_id="O2" value="11.04" spread="40.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Cytokines - IL-8</title>
        <description>Inflammatory and non-inflammatory cytokines levels will be tested in plasma at baseline and 6 months after intervention. We are reporting levels of IL-8 here.</description>
        <time_frame>at baseline and after 6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Niacin</title>
            <description>Niacin 250 mg is compared to placebo tablet.&#xD;
niacin: Niacin or nicotinic acid 250 mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo&#xD;
placebo: placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Cytokines - IL-8</title>
          <description>Inflammatory and non-inflammatory cytokines levels will be tested in plasma at baseline and 6 months after intervention. We are reporting levels of IL-8 here.</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="2.2"/>
                    <measurement group_id="O2" value="6.2" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="3.5"/>
                    <measurement group_id="O2" value="6.6" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Cytokines - TNF-alpha</title>
        <description>Inflammatory and non-inflammatory cytokines levels will be tested in plasma at baseline and 6 months after intervention. We are reporting levels of TNF-alpha here.</description>
        <time_frame>at baseline and after 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Niacin</title>
            <description>Niacin 250 mg is compared to placebo tablet.&#xD;
niacin: Niacin or nicotinic acid 250 mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo&#xD;
placebo: placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Cytokines - TNF-alpha</title>
          <description>Inflammatory and non-inflammatory cytokines levels will be tested in plasma at baseline and 6 months after intervention. We are reporting levels of TNF-alpha here.</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.05" spread="4.7"/>
                    <measurement group_id="O2" value="0.96" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.26" spread="5.2"/>
                    <measurement group_id="O2" value="1.0" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Cytokines - IP-10</title>
        <description>Inflammatory and non-inflammatory cytokines levels will be tested in plasma at baseline and 6 months after intervention. We are reporting levels of IP-10 here.</description>
        <time_frame>at baseline and after 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Niacin</title>
            <description>Niacin 250 mg is compared to placebo tablet.&#xD;
niacin: Niacin or nicotinic acid 250 mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo&#xD;
placebo: placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Cytokines - IP-10</title>
          <description>Inflammatory and non-inflammatory cytokines levels will be tested in plasma at baseline and 6 months after intervention. We are reporting levels of IP-10 here.</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="443.3" spread="197.3"/>
                    <measurement group_id="O2" value="402.7" spread="252.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="542.1" spread="295.8"/>
                    <measurement group_id="O2" value="355.4" spread="158.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Cytokines - MCP-4</title>
        <description>Inflammatory and non-inflammatory cytokines levels will be tested in plasma at baseline and 6 months after intervention. We are reporting levels of MCP-4 here.</description>
        <time_frame>at baseline and after 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Niacin</title>
            <description>Niacin 250 mg is compared to placebo tablet.&#xD;
niacin: Niacin or nicotinic acid 250 mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo&#xD;
placebo: placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Cytokines - MCP-4</title>
          <description>Inflammatory and non-inflammatory cytokines levels will be tested in plasma at baseline and 6 months after intervention. We are reporting levels of MCP-4 here.</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.3" spread="73.8"/>
                    <measurement group_id="O2" value="104.6" spread="35.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.4" spread="44"/>
                    <measurement group_id="O2" value="90.7" spread="41.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Cytokines - MIP1-alpha</title>
        <description>Inflammatory and non-inflammatory cytokines levels will be tested in plasma at baseline and 6 months after intervention. We are reporting levels of MIP1-alpha here.</description>
        <time_frame>at baseline and after 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Niacin</title>
            <description>Niacin 250 mg is compared to placebo tablet.&#xD;
niacin: Niacin or nicotinic acid 250 mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo&#xD;
placebo: placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Cytokines - MIP1-alpha</title>
          <description>Inflammatory and non-inflammatory cytokines levels will be tested in plasma at baseline and 6 months after intervention. We are reporting levels of MIP1-alpha here.</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3" spread="20.5"/>
                    <measurement group_id="O2" value="42.1" spread="116.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.2" spread="9.3"/>
                    <measurement group_id="O2" value="38.9" spread="75.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Cytokines - MIP1-beta</title>
        <description>Inflammatory and non-inflammatory cytokines levels will be tested in plasma at baseline and 6 months after intervention. We are reporting levels of MIP1-beta here.</description>
        <time_frame>at baseline and after 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Niacin</title>
            <description>Niacin 250 mg is compared to placebo tablet.&#xD;
niacin: Niacin or nicotinic acid 250 mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo&#xD;
placebo: placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Cytokines - MIP1-beta</title>
          <description>Inflammatory and non-inflammatory cytokines levels will be tested in plasma at baseline and 6 months after intervention. We are reporting levels of MIP1-beta here.</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.3" spread="26.1"/>
                    <measurement group_id="O2" value="65.8" spread="29.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.5" spread="34.5"/>
                    <measurement group_id="O2" value="56" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Levels - Serotonin</title>
        <description>Plasma serotonin levels</description>
        <time_frame>at baseline and after 6 months</time_frame>
        <population>a subset of the groups were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Niacin</title>
            <description>Niacin 250 mg is compared to placebo tablet.&#xD;
niacin: Niacin or nicotinic acid 250 mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo&#xD;
placebo: placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Levels - Serotonin</title>
          <description>Plasma serotonin levels</description>
          <population>a subset of the groups were analyzed.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.2" spread="68.2"/>
                    <measurement group_id="O2" value="89.6" spread="60.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" spread="75.2"/>
                    <measurement group_id="O2" value="64.2" spread="44.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Niacin</title>
          <description>Niacin 250 mg is compared to placebo tablet.&#xD;
niacin: Niacin or nicotinic acid 250 mg tablets</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo&#xD;
placebo: placebo tablet</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>flushing</sub_title>
                <description>minimal flushing on either face or trunk</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Additional studies are required including a larger cohort and multi-center to further generalize findings, as well as comparing niacin to placebo for longer than 6 months before optimal information can be obtained for use in clinical settings.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Chandramohan Wakade</name_or_title>
      <organization>Charlie Norwood VAMC</organization>
      <phone>706-733-0188 ext 2379</phone>
      <email>chandramohan.wakade@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

